8-K: GRAIL Inc. Announces Preliminary 2024 Results and Outlines 2025 Priorities at J.P. Morgan Healthcare Conference

GRAIL, Inc. presented a corporate update and preliminary financial information for the quarter and year ended December 31, 2024, at the 2025 J.P. Morgan Healthcare Conference, highlighting commercial growth, clinical validation, and strategic priorities.

Summary

• GRAIL, Inc. presented at the J.P. Morgan Healthcare Conference in January 2025, providing a corporate update and preliminary financial results for 2024.
• The company sold approximately 137,000 Galleri tests in FY24 and has over 13,000 ordering providers.
• GRAIL's Galleri test aims to detect cancer early, when it can be cured, addressing the limitations of current screening methods.
• The company is targeting completion of a modular PMA submission to the FDA in the first half of 2026.
• Preliminary revenue for 2024 is estimated between $124 million and $126 million, with U.S. Galleri revenue between $107 million and $110 million.
• GRAIL projects 20-30% growth in U.S. Galleri sales for 2025 and anticipates a cash burn of less than $320 million.
• The company's cash balance as of December 31, 2024, was $767 million, providing a runway into 2028.
• GRAIL has launched a new version of Galleri in December 2024 with enhanced cancer signal of origin (CSO) prediction.
• The company has invested significantly in clinical programs, including approximately 385,000 participants enrolled or to be enrolled across studies.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for GRAIL, highlighting commercial growth, clinical validation, and a strong cash position. While acknowledging risks and uncertainties, the overall tone is optimistic.

Positives

• Galleri has demonstrated the ability to detect asymptomatic deadly cancers in clinical practice.
• The company has seen robust Galleri adoption and strong partnerships.
• Galleri has a very low false positive rate.
• The new version of Galleri launched in December 2024 offers scalability and CSO enhancements.
• GRAIL has a significant global addressable market for its multi-cancer early detection test.
• The company has a leading clinical program with over 300 publications and presentations.

Negatives

• The financial results presented are preliminary and unaudited, and actual results could be materially different.
• The presentation contains forward-looking statements that are subject to risks and uncertainties.

Risks

• The company operates in a dynamic and rapidly changing environment, and new risks emerge from time to time.
• The company's actual results and financial condition may differ materially from those indicated in the forward-looking statements.
• The company's ability to achieve FDA approval and CMS coverage for Galleri is uncertain.

Future Outlook

GRAIL anticipates 20-30% growth in U.S. Galleri sales for 2025 and expects to complete its modular PMA submission to the FDA in the first half of 2026. The company's cash balance provides a runway into 2028.

Management Comments

• Bob Ragusa, CEO, presented at the J.P. Morgan Healthcare Conference in January 2025.
• Tad Carper, SVP Dallas Cowboys & Galleri patient, stated 'I just want to encourage others to get tested even when you're feeling fine. That's the best time -the best time -to do something like this. If I had waited another two to three months, when my throat started to hurt, the doctors have told me we'd be having a much different conversation.'

Industry Context

GRAIL is positioned as a leader in the multi-cancer early detection (MCED) market, addressing a significant unmet need in cancer screening. The company's Galleri test competes with other emerging technologies in the liquid biopsy space, aiming to improve early cancer detection rates and patient outcomes.

Comparison to Industry Standards

• The Galleri test's positive predictive value (PPV) of 43% in the PATHFINDER study compares favorably to PPVs for existing screening methods like FIT (1.2%), LDCT (3.8%), and mammography (4.4%).
• GRAIL's focus on population-scale screening aligns with the broader industry trend towards early detection and personalized medicine.
• The company's clinical program, with approximately 385,000 participants, is substantial compared to many other diagnostic companies.

Stakeholder Impact

• Shareholders: The update provides insights into the company's financial performance and strategic direction.
• Employees: The company's focus on strategic priorities and cost management may impact employees.
• Customers: The launch of the new Galleri version and pursuit of reimbursement may improve access to the test.
• Patients: Early cancer detection through Galleri has the potential to improve patient outcomes.

Next Steps

• Seek FDA approval of Galleri.
• Pursue CMS coverage and broad commercial reimbursement for Galleri.
• Complete registrational trial data (PATHFINDER 2 and NHS).
• Complete modular PMA submission to FDA.

Key Dates